Literature DB >> 23954142

A balance of interleukin-12 and -23 in cancer.

Shin Foong Ngiow1, Michele W L Teng, Mark J Smyth.   

Abstract

Interleukin (IL)-12 and IL-23 share the IL-12p40 molecule. IL-12 promotes T helper (Th)1 immunity and IL-23 promotes Th17 immunity, and it has recently become apparent that the balance between IL-12 and IL-23 is important in carcinogenesis. A series of studies demonstrated that, where tumor initiation, growth, and metastasis are concerned, IL-12 may act independently of interferon (IFN)-γ, and IL-23 independently of IL-17A. This review explores the activity of IL-23 in carcinogenesis. In the context of the tumor-inhibitory effects of IL-12, and tumor-promoting effects of IL-23, we discuss the use of anti-IL-12p/23 monoclonal antibodies (mAbs) in autoimmune inflammatory disorders and the alternative specific neutralization of IL-23.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  autoimmunity; cancer; cytokine; inflammation

Mesh:

Substances:

Year:  2013        PMID: 23954142     DOI: 10.1016/j.it.2013.07.004

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  52 in total

1.  Prostaglandin E2 activates the mTORC1 pathway through an EP4/cAMP/PKA- and EP1/Ca2+-mediated mechanism in the human pancreatic carcinoma cell line PANC-1.

Authors:  Hui-Hua Chang; Steven H Young; James Sinnett-Smith; Caroline Ei Ne Chou; Aune Moro; Kathleen M Hertzer; Oscar Joe Hines; Enrique Rozengurt; Guido Eibl
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-26       Impact factor: 4.249

Review 2.  Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer.

Authors:  Juming Yan; Mark J Smyth; Michele W L Teng
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

3.  Characterization of an IL-12 p40/p35 Truncated Fusion Protein That can Inhibit the Action of IL-12.

Authors:  Denise Skrombolas; Isabel Wylie; Shivana Maharaj; John G Frelinger
Journal:  J Interferon Cytokine Res       Date:  2015-05-04       Impact factor: 2.607

Review 4.  IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.

Authors:  Michele W L Teng; Edward P Bowman; Joshua J McElwee; Mark J Smyth; Jean-Laurent Casanova; Andrea M Cooper; Daniel J Cua
Journal:  Nat Med       Date:  2015-06-29       Impact factor: 53.440

Review 5.  Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.

Authors:  Noelia Purroy; Catherine J Wu
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

6.  Interleukin-23 engineering improves CAR T cell function in solid tumors.

Authors:  Xingcong Ma; Yang Xu; Peishun Shou; Christof Smith; Yuhui Chen; Hongwei Du; Chuang Sun; Nancy Porterfield Kren; Daniel Michaud; Sarah Ahn; Benjamin Vincent; Barbara Savoldo; Yuliya Pylayeva-Gupta; Shuqun Zhang; Gianpietro Dotti
Journal:  Nat Biotechnol       Date:  2020-02-03       Impact factor: 54.908

7.  Clinical improvement in psoriasis with specific targeting of interleukin-23.

Authors:  Tamara Kopp; Elisabeth Riedl; Christine Bangert; Edward P Bowman; Elli Greisenegger; Ann Horowitz; Harald Kittler; Wendy M Blumenschein; Terrill K McClanahan; Thomas Marbury; Claus Zachariae; Danlin Xu; Xiaoli Shirley Hou; Anish Mehta; Anthe S Zandvliet; Diana Montgomery; Frank van Aarle; Sauzanne Khalilieh
Journal:  Nature       Date:  2015-03-09       Impact factor: 49.962

8.  Effect of continuous positive airway pressure (CPAP) therapy on IL-23 in patients with obstructive sleep apnea.

Authors:  Murat Can; Fırat Uygur; Hakan Tanrıverdi; Bilgehan Acıkgoz; Barıs Alper; Berrak Guven
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

Review 9.  Moving towards personalized treatments of immune-related adverse events.

Authors:  Khashayar Esfahani; Arielle Elkrief; Cassandra Calabrese; Réjean Lapointe; Marie Hudson; Bertrand Routy; Wilson H Miller; Leonard Calabrese
Journal:  Nat Rev Clin Oncol       Date:  2020-04-03       Impact factor: 66.675

Review 10.  Combination cancer immunotherapies tailored to the tumour microenvironment.

Authors:  Mark J Smyth; Shin Foong Ngiow; Antoni Ribas; Michele W L Teng
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.